NBY
Price
$0.58
Change
-$0.01 (-1.69%)
Updated
Jun 6 closing price
Capitalization
3.43M
NCNA
Price
$0.05
Change
+$0.01 (+25.00%)
Updated
Jun 6 closing price
Capitalization
238.04K
Interact to see
Advertisement

NBY vs NCNA

Header iconNBY vs NCNA Comparison
Open Charts NBY vs NCNABanner chart's image
NovaBay Pharmaceuticals
Price$0.58
Change-$0.01 (-1.69%)
Volume$20.5K
Capitalization3.43M
NuCana
Price$0.05
Change+$0.01 (+25.00%)
Volume$301.43M
Capitalization238.04K
NBY vs NCNA Comparison Chart
Loading...
NBY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NCNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
NBY vs. NCNA commentary
Jun 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NBY is a Buy and NCNA is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 07, 2025
Stock price -- (NBY: $0.56 vs. NCNA: $0.04)
Brand notoriety: NBY and NCNA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NBY: 42% vs. NCNA: 109%
Market capitalization -- NBY: $3.43M vs. NCNA: $238.04K
NBY [@Biotechnology] is valued at $3.43M. NCNA’s [@Biotechnology] market capitalization is $238.04K. The market cap for tickers in the [@Biotechnology] industry ranges from $323.27B to $0. The average market capitalization across the [@Biotechnology] industry is $2.25B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NBY’s FA Score shows that 1 FA rating(s) are green whileNCNA’s FA Score has 1 green FA rating(s).

  • NBY’s FA Score: 1 green, 4 red.
  • NCNA’s FA Score: 1 green, 4 red.
According to our system of comparison, NBY is a better buy in the long-term than NCNA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NBY’s TA Score shows that 5 TA indicator(s) are bullish while NCNA’s TA Score has 5 bullish TA indicator(s).

  • NBY’s TA Score: 5 bullish, 4 bearish.
  • NCNA’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, NCNA is a better buy in the short-term than NBY.

Price Growth

NBY (@Biotechnology) experienced а +0.43% price change this week, while NCNA (@Biotechnology) price change was -7.18% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.11%. For the same industry, the average monthly price growth was +10.01%, and the average quarterly price growth was -2.16%.

Industries' Descriptions

@Biotechnology (+4.11% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NBY($3.43M) has a higher market cap than NCNA($238K). NBY YTD gains are higher at: -6.406 vs. NCNA (-96.849). NBY has higher annual earnings (EBITDA): -6.52M vs. NCNA (-22.48M). NCNA has more cash in the bank: 6.75M vs. NBY (776K). NCNA has less debt than NBY: NCNA (190K) vs NBY (1.26M). NBY has higher revenues than NCNA: NBY (13.8M) vs NCNA (0).
NBYNCNANBY / NCNA
Capitalization3.43M238K1,441%
EBITDA-6.52M-22.48M29%
Gain YTD-6.406-96.8497%
P/E Ratio0.02N/A-
Revenue13.8M0-
Total Cash776K6.75M11%
Total Debt1.26M190K664%
FUNDAMENTALS RATINGS
NBY vs NCNA: Fundamental Ratings
NBY
NCNA
OUTLOOK RATING
1..100
288
VALUATION
overvalued / fair valued / undervalued
1..100
13
Undervalued
7
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10099
PRICE GROWTH RATING
1..100
8299
P/E GROWTH RATING
1..100
58100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NCNA's Valuation (7) in the Biotechnology industry is in the same range as NBY (13). This means that NCNA’s stock grew similarly to NBY’s over the last 12 months.

NCNA's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as NBY (100). This means that NCNA’s stock grew similarly to NBY’s over the last 12 months.

NCNA's SMR Rating (99) in the Biotechnology industry is in the same range as NBY (100). This means that NCNA’s stock grew similarly to NBY’s over the last 12 months.

NBY's Price Growth Rating (82) in the Biotechnology industry is in the same range as NCNA (99). This means that NBY’s stock grew similarly to NCNA’s over the last 12 months.

NBY's P/E Growth Rating (58) in the Biotechnology industry is somewhat better than the same rating for NCNA (100). This means that NBY’s stock grew somewhat faster than NCNA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NBYNCNA
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 11 days ago
81%
Bullish Trend 11 days ago
83%
Momentum
ODDS (%)
Bearish Trend 11 days ago
90%
Bullish Trend 11 days ago
78%
MACD
ODDS (%)
Bearish Trend 11 days ago
90%
Bullish Trend 11 days ago
78%
TrendWeek
ODDS (%)
Bearish Trend 11 days ago
90%
Bearish Trend 11 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 11 days ago
90%
Bearish Trend 11 days ago
90%
Advances
ODDS (%)
Bullish Trend 20 days ago
82%
Bullish Trend 24 days ago
79%
Declines
ODDS (%)
Bearish Trend 11 days ago
90%
Bearish Trend 17 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 11 days ago
90%
Bullish Trend 11 days ago
89%
Aroon
ODDS (%)
Bullish Trend 11 days ago
86%
Bearish Trend 11 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
NBY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NCNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AAPL200.420.21
+0.10%
Apple
SPY587.73-3.42
-0.58%
SPDR® S&P 500® ETF
BTC.X107802.330000-1192.312500
-1.09%
Bitcoin cryptocurrency
TSLA356.90-5.99
-1.65%
Tesla
GME31.21-3.80
-10.85%
GameStop Corp

NBY and

Correlation & Price change

A.I.dvisor indicates that over the last year, NBY has been closely correlated with CDTX. These tickers have moved in lockstep 93% of the time. This A.I.-generated data suggests there is a high statistical probability that if NBY jumps, then CDTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NBY
1D Price
Change %
NBY100%
-0.58%
CDTX - NBY
93%
Closely correlated
-5.46%
NCNA - NBY
93%
Closely correlated
-3.85%
WINT - NBY
92%
Closely correlated
+5.12%
SNPX - NBY
91%
Closely correlated
-10.74%
RNAC - NBY
91%
Closely correlated
+3.65%
More

NCNA and

Correlation & Price change

A.I.dvisor indicates that over the last year, NCNA has been closely correlated with CDTX. These tickers have moved in lockstep 93% of the time. This A.I.-generated data suggests there is a high statistical probability that if NCNA jumps, then CDTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NCNA
1D Price
Change %
NCNA100%
-3.85%
CDTX - NCNA
93%
Closely correlated
-5.46%
NBY - NCNA
92%
Closely correlated
-0.58%
WINT - NCNA
92%
Closely correlated
+5.12%
RNAC - NCNA
92%
Closely correlated
+3.65%
SNPX - NCNA
92%
Closely correlated
-10.74%
More